Arteriovenous Fistula Maturation Failure in End-stage Renal Disease
Study summary
This study aims to investigate the long-term clinical outcomes and molecular mechanisms of autogenous arteriovenous fistula (AVF) maturation failure in uremic patients. The primary goal is to develop a precision prediction model integrating clinical, imaging, and biomarker data, while secondary objectives focus on identifying key molecular targets regulating AVF maturation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age ≥18 years
2. Diagnosed with chronic kidney disease stage 5 (ESRD) and scheduled for first-time autogenous AVF creation
3. No severe coagulation disorders or vascular malformations
4. Willing to provide written informed consent
5. Planned hemodialysis at the study center
Exclusion Criteria:
1. Previous AVF surgery on the ipsilateral limb
2. Ipsilateral central venous stenosis or significant venous outflow obstruction
3. Active malignancy (except localized non-melanoma skin cancer)
4. Active infection at the surgical site
5. Life expectancy \<1 year
6. Pregnancy or lactation
7. Participation in other interventional trials
Primary outcome measure(s)
Arteriovenous fistula maturation failure rate — 6 weeks and 6 months post-surgery Failure to meet KDOQI criteria at 6 weeks post-operation (blood flow \<600 mL/min, venous diameter \<6 mm, OR subcutaneous depth \>6 mm) AND inability to sustain hemodialysis (2 sessions/week)
Trial sites (1)
Facility
City
Region
Status
Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.